Post-Stroke Spasticity Management
Spasticity develops in approximately 20–40% of stroke survivors, typically emerging days to weeks after the acute event as upper motor neuron pathways undergo reorganization. It is defined as a velocity-dependent increase in tonic stretch reflexes resulting from hyperexcitability of the stretch reflex — clinically manifesting as increased resistance to passive movement that is greater at higher speeds. Spasticity is not merely a physical examination finding: it causes pain, limits mobility and ADL performance, promotes contractures, impairs hygiene, and is one of the most significant barriers to functional recovery. Conversely, when appropriately managed, spasticity treatment can dramatically improve quality of life, reduce caregiver burden, and unlock latent functional capacity.
🔹 Bottom Line: Spasticity Management
- Not all spasticity requires treatment: Mild spasticity can be functionally beneficial (e.g., quadriceps tone aiding standing). Treat when spasticity causes pain, limits function, impairs hygiene, or prevents positioning.
- Botulinum toxin is the first-line focal treatment (Level A evidence). OnabotulinumtoxinA, abobotulinumtoxinA, and incobotulinumtoxinA are all FDA-approved for post-stroke upper and lower limb spasticity.
- Assess before injecting: Distinguish spasticity (velocity-dependent, reducible) from contracture (fixed, non-reducible). Botulinum toxin treats spasticity — it does not resolve contracture.
- Combine modalities: Botulinum toxin + stretching + functional therapy produces better outcomes than any single intervention alone.
- Oral agents (baclofen, tizanidine, dantrolene) have limited evidence in stroke-specific spasticity and cause sedation that impairs rehabilitation. Use as adjuncts, not first-line.
- Intrathecal baclofen (ITB): Consider for severe, generalized lower extremity spasticity refractory to botulinum toxin and oral agents. Requires surgical pump implantation with long-term maintenance.
- Prevention: Early range of motion, proper positioning, and splinting can delay or reduce the severity of spasticity.
1. Pathophysiology for the Practicing Neurologist
Understanding the mechanism of spasticity helps guide treatment selection. Post-stroke spasticity results from loss of descending inhibitory input — primarily from the dorsal reticulospinal tract — to spinal motor neurons and interneurons. This disinhibition produces hyperexcitable stretch reflexes and increased alpha motor neuron activity. Several pathways contribute:
- Loss of corticoreticulospinal inhibition: The dorsal reticulospinal tract (originating from the medullary reticular formation) normally provides tonic inhibition to spinal reflexes. Stroke-related damage to cortical or subcortical projections to this nucleus releases that inhibition, resulting in hyperactive stretch reflexes. This is the primary mechanism in most post-stroke spasticity.
- Unopposed medial reticulospinal and vestibulospinal facilitation: These descending pathways, which facilitate extensor tone, become relatively hyperactive when the inhibitory dorsal reticulospinal pathway is damaged. This produces the classic hemiplegic posture: upper extremity flexion (biceps, wrist/finger flexors) and lower extremity extension (quadriceps, ankle plantarflexors).
- Spinal cord reorganization: Over weeks to months, denervation hypersensitivity of alpha motor neurons, sprouting of afferent interneurons, and reduction in presynaptic inhibition produce progressive changes in spinal circuits that make spasticity a dynamic, evolving phenomenon — not a static condition.
- Secondary peripheral changes: Prolonged spasticity causes muscle fibre type transformation (fast-to-slow), collagen deposition, loss of sarcomeres, and shortened resting muscle length. These changes produce contracture — a fixed structural shortening that will not respond to antispastic treatment. Distinguishing spasticity from contracture on examination is essential before initiating treatment.
2. Clinical Assessment
Modified Ashworth Scale (MAS)
The Modified Ashworth Scale is the most widely used clinical assessment for spasticity and is reported in virtually all botulinum toxin trials and rehabilitation documentation. It grades resistance to passive stretch on a 6-point ordinal scale:
| Grade | Description | Clinical Interpretation |
|---|---|---|
| 0 | No increase in muscle tone | Normal |
| 1 | Slight increase in tone — a "catch" at end of range, or minimal resistance through <50% of ROM | Mild spasticity. Often no functional impact. May be beneficial (e.g., quad tone for standing). |
| 1+ | Slight increase in tone — a catch followed by minimal resistance through >50% of remaining ROM | Mild-moderate. May begin to limit rapid movements and fine motor tasks. |
| 2 | More marked increase in tone through most of ROM, but limb easily moved passively | Moderate. Functionally significant. Likely impairs dressing, hygiene, gait. Most common grade at which treatment is initiated. |
| 3 | Considerable increase in tone — passive movement is difficult | Severe. Significant pain, hygiene issues, positioning difficulty. Often requires multi-modal treatment. |
| 4 | Rigid — affected part in fixed flexion or extension | May represent contracture rather than (or in addition to) spasticity. Examine under sedation or after nerve block to differentiate. |
Modified Tardieu Scale (MTS)
The Modified Tardieu Scale has a theoretical advantage over the MAS because it directly tests the velocity-dependent nature of spasticity — the defining feature that distinguishes it from contracture. The examiner passively moves the joint at two speeds: slow (V1 — as slow as possible) and fast (V3 — as fast as possible). Two measurements are recorded:
- R1: The angle of "catch" (or clonus) during fast passive stretch — this is the angle at which spasticity activates.
- R2: The full passive ROM achieved at slow velocity — this is the structural limit (limited by contracture if present).
- R2 − R1 difference: This quantifies the dynamic component (spasticity) versus the fixed component (contracture). A large R2 − R1 difference means most of the restriction is from spasticity (treatable with botulinum toxin). A small or zero R2 − R1 difference means the restriction is from contracture (requires serial casting, surgical intervention, or acceptance).
🔹 Clinical Relevance: Spasticity vs Contracture — Why It Matters Before Injecting
- Spasticity (dynamic): Velocity-dependent resistance. R2 − R1 difference is large on Tardieu. Passive ROM under sedation is near-normal. Responds to botulinum toxin, stretching, oral antispastics.
- Contracture (fixed): Non-velocity-dependent resistance. R2 − R1 difference is small or zero. Passive ROM under sedation remains restricted. Does NOT respond to botulinum toxin alone. Requires serial casting, dynamic splinting, or surgical release.
- Mixed (most common): Both components present. Treat the spasticity component first (botulinum toxin + stretching); reassess the residual fixed component; consider serial casting for remaining contracture.
- Common mistake: Injecting botulinum toxin into a contractured muscle and being disappointed by lack of improvement. Always assess R2 − R1 before treatment planning.
Goal-Oriented Assessment
Before initiating any spasticity treatment, define the treatment goal explicitly. Spasticity is not treated in a vacuum — treatment is justified by the functional or symptomatic problem it is causing. Treatment goals fall into four categories, ordered from most to least ambitious:
| Goal Category | Examples | Assessment Tools |
|---|---|---|
| Active function | Improve reaching, grasping, walking speed, stair climbing | ARAT, FMA-UE, Timed Up and Go, 10-Meter Walk Test, Goal Attainment Scaling (GAS) |
| Passive function | Ease dressing, improve hand hygiene (palm cleaning), facilitate perineal care, improve wheelchair positioning | Disability Assessment Scale (DAS), GAS, caregiver-reported outcomes |
| Pain reduction | Reduce spasticity-related pain in shoulder, hand, calf; reduce painful spasms interfering with sleep | Numeric Rating Scale (NRS), Visual Analog Scale (VAS), Penn Spasm Frequency Scale |
| Prevention | Prevent contracture development, maintain ROM, prevent skin breakdown in flexion creases | Serial goniometry, skin inspection, Tardieu R2 measurements over time |
3. Pharmacologic Treatment: Botulinum Toxin
Botulinum toxin injection is the first-line treatment for focal post-stroke spasticity and has Level A evidence across multiple systematic reviews and guidelines (AAN Practice Guidelines, European Consensus). Three formulations are FDA-approved for adult upper and/or lower limb spasticity:
| Formulation | Brand | FDA-Approved Indications (Stroke-Relevant) | Typical Dose Range (Total per Session) | Units Not Interchangeable |
|---|---|---|---|---|
| OnabotulinumtoxinA | Botox | Upper limb spasticity (adult), lower limb spasticity (adult) | 200–400 U upper limb; 300–400 U lower limb; max ~600 U total | Units are NOT interchangeable between formulations. Ona:Abo ratio is approximately 1:2.5–3. Ona:Inco ratio is approximately 1:1. |
| AbobotulinumtoxinA | Dysport | Upper limb spasticity (adult), lower limb spasticity (adult) | 500–1000 U upper limb; 1000–1500 U lower limb | |
| IncobotulinumtoxinA | Xeomin | Upper limb spasticity (adult) | 200–400 U upper limb |
Mechanism
Botulinum toxin cleaves SNARE proteins (specifically SNAP-25 for type A) at the presynaptic neuromuscular junction, preventing acetylcholine vesicle fusion and release. This produces a reversible chemodenervation of the injected muscle. Clinical effect begins 3–7 days post-injection, peaks at 2–6 weeks, and wears off over 3–4 months as new synaptic terminals sprout. Repeat injections are typically performed every 12–16 weeks.
Upper Limb Injection Patterns
Post-stroke upper limb spasticity follows predictable patterns related to the hemiplegic posture: shoulder adduction/internal rotation, elbow flexion, forearm pronation, wrist flexion, finger flexion, and thumb-in-palm. Injection targets are selected based on the specific pattern causing the patient's functional problem.
| Pattern | Target Muscles | OnabotulinumtoxinA Dose (Units) | Functional Impact |
|---|---|---|---|
| Shoulder adduction / internal rotation | Pectoralis major, subscapularis, latissimus dorsi, teres major | Pec major: 75–150 U (3–4 sites); Subscap: 50–100 U (2 sites); Lat dorsi: 50–100 U; Teres major: 25–50 U | Pain relief, improved hygiene (axillary access), easier dressing, reduced shoulder impingement |
| Elbow flexion | Biceps brachii, brachialis, brachioradialis | Biceps: 100–200 U (4 sites); Brachialis: 50–75 U (2 sites); Brachioradialis: 50–75 U (2 sites) | Easier dressing (sleeve donning), improved reaching, hygiene of antecubital fossa |
| Forearm pronation | Pronator teres, pronator quadratus | PT: 50–75 U (2 sites); PQ: 25–50 U (1 site) | Improved supination for feeding, opening palm |
| Wrist flexion | Flexor carpi radialis (FCR), flexor carpi ulnaris (FCU) | FCR: 25–50 U (1–2 sites); FCU: 25–50 U (1–2 sites) | Improved wrist position for grasp, easier splint application, reduced tenodesis effect |
| Finger flexion (clenched fist) | Flexor digitorum superficialis (FDS), flexor digitorum profundus (FDP) | FDS: 25–50 U (2 sites); FDP: 25–50 U (2 sites) | Palm hygiene (critical — maceration and infection occur in clenched fists), improved grasp/release |
| Thumb-in-palm | Flexor pollicis longus (FPL), adductor pollicis, flexor pollicis brevis (FPB), opponens pollicis | FPL: 10–25 U; Adductor poll: 10–20 U; FPB: 10–20 U | Improved grasp aperture, reduced thumb pain and nail-digging into palm |
Lower Limb Injection Patterns
| Pattern | Target Muscles | OnabotulinumtoxinA Dose (Units) | Functional Impact |
|---|---|---|---|
| Equinovarus foot | Gastrocnemius (medial & lateral heads), soleus, tibialis posterior | Gastroc med: 75–100 U (2 sites); Gastroc lat: 75–100 U (2 sites); Soleus: 75–100 U (2 sites); Tib posterior: 50–75 U (1–2 sites) | Improved foot flat contact during stance, reduced toe-walking, improved AFO fit, reduced calf pain |
| Striatal toe (extensor hallucis) | Extensor hallucis longus (EHL) | EHL: 50–100 U (1–2 sites) | Improved shoe fit, reduced pressure sore on dorsum of great toe |
| Curled/clawed toes | Flexor digitorum longus (FDL), flexor digitorum brevis (FDB) | FDL: 50–75 U (2 sites); FDB: 25–50 U (2 sites) | Reduced pain at toe tips, improved shoe wearing, reduced calluses |
| Knee flexion (stiff knee / crouched gait) | Hamstrings (semimembranosus, semitendinosus, biceps femoris) | Medial hams: 75–100 U (2 sites); Lateral ham: 75–100 U (2 sites) | Improved stance phase knee extension, reduced crouch |
| Adductor spasticity (scissoring) | Adductor longus, adductor magnus, gracilis | Add longus: 75–100 U; Add magnus: 75–100 U; Gracilis: 50–75 U | Improved gait width (reduced scissoring), easier perineal hygiene, catheter care |
Injection Guidance
Injection accuracy directly determines clinical outcomes. Three guidance methods are used, with evidence supporting guided techniques over anatomic landmark approaches:
| Guidance Method | How It Works | Best For | Limitations |
|---|---|---|---|
| Ultrasound (US) | Real-time imaging of muscle, needle tip, and surrounding structures (vessels, nerves) | Deep muscles (subscapularis, FDP, tibialis posterior, pronator quadratus), forearm compartment muscles difficult to palpate | Requires US machine and training. Increasingly considered standard of care — most evidence supports superior outcomes compared to landmark technique. |
| EMG/Electrical stimulation | Needle connected to EMG; electrical stimulation through the needle causes muscle contraction, confirming needle is in target muscle | Differentiating overlapping muscles (FDS vs FDP, gastroc vs soleus), confirming target in obese patients | Mildly uncomfortable for patient (stimulation). Cannot visualize vessels/nerves. Often combined with US for best accuracy. |
| Anatomic landmarks | Palpation of bony landmarks and muscle bellies to estimate injection site | Superficial, easily palpable muscles (biceps, gastroc, pec major) | Significantly less accurate for deep muscles. Associated with worse outcomes in comparative studies. Should be limited to superficial targets. |
🔹 Clinical Relevance: Maximizing Botulinum Toxin Outcomes
- Timing of therapy: Begin intensive stretching 1 week after injection (when toxin effect begins), not immediately. The 2–6 week peak effect window is the optimal time for aggressive ROM, serial casting, and functional therapy.
- Combination approach: Botulinum toxin + structured physical therapy + task-specific practice produces significantly better outcomes than botulinum toxin alone. Always pair injections with a therapy prescription.
- Reassess at 4–6 weeks: If inadequate response, consider whether the correct muscles were targeted (re-evaluate pattern), whether dosing was adequate (titrate up next cycle), whether contracture is the primary component (R2 − R1 reassessment), or whether injection guidance was suboptimal.
- Antibody formation: Neutralizing antibodies develop in ~1–5% of patients with repeated injections, causing secondary non-response. Risk is higher with higher doses and shorter injection intervals. If suspected, switch formulations (ona → inco or abo). IncobotulinumtoxinA has theoretically lower immunogenicity due to absence of complexing proteins.
- Avoid excessive weakening: Overly aggressive dosing can convert useful tone into unwanted weakness. A quadriceps with MAS 2 that helps the patient stand may be worse at MAS 0 with profound weakness. Treat the problem, not the number.
4. Oral Antispastic Medications
Oral antispastic agents are commonly prescribed but have limited evidence in post-stroke spasticity specifically. Most trial data derives from spinal cord injury and multiple sclerosis populations. In stroke, these agents carry a significant risk-benefit tradeoff: sedation, cognitive impairment, and weakness can all impair rehabilitation participation and functional recovery.
| Drug | Mechanism | Dosing | Stroke-Specific Considerations |
|---|---|---|---|
| Baclofen | GABAB receptor agonist — reduces excitatory neurotransmitter release at spinal level | Start 5 mg TID, titrate by 5 mg/dose every 3 days. Max 80 mg/day (usually 40–60 mg effective). Must taper to discontinue (seizure risk with abrupt withdrawal). | Most commonly used oral agent. Significant sedation and cognitive impairment limit effectiveness in stroke patients actively participating in rehab. Can worsen urinary retention. Lowers seizure threshold if stopped abruptly. |
| Tizanidine | Alpha-2 adrenergic agonist — reduces excitatory amino acid release from spinal interneurons | Start 2 mg at bedtime, titrate by 2 mg every 3–4 days. Max 36 mg/day in divided doses (TID). Monitor LFTs at baseline, 1, 3, 6 months. | May cause less weakness than baclofen (theoretical advantage for stroke). Causes sedation, hypotension, dry mouth, dizziness. Hepatotoxicity risk (~5% LFT elevation, rare fulminant hepatitis). Useful as nighttime dose for nocturnal spasms. |
| Dantrolene | Peripheral — inhibits calcium release from sarcoplasmic reticulum, reducing muscle contraction force | Start 25 mg daily, titrate weekly. Max 100 mg QID (400 mg/day). Monitor LFTs. | Only antispastic that acts peripherally (no CNS sedation). However, causes generalized weakness — problematic in stroke patients who need every ounce of strength. Hepatotoxicity risk (most dangerous of oral agents — fatal hepatitis reported). Rarely used in stroke. |
| Diazepam | GABAA receptor potentiator — enhances presynaptic inhibition in spinal cord | 2–10 mg BID-TID | Generally avoided in stroke. Significant sedation, cognitive impairment, fall risk, dependence potential. May impair neuroplasticity. Consider only for acute severe spasticity crisis or refractory nocturnal spasms as a short-term bridge. |
🔴 Oral Antispastics: Key Safety Warnings
- Sedation impairs rehab: All centrally acting agents (baclofen, tizanidine, diazepam) can reduce therapy participation, impair cognition, and increase fall risk — directly counteracting rehabilitation goals.
- Baclofen withdrawal: Abrupt discontinuation can cause seizures, hallucinations, and autonomic instability resembling neuroleptic malignant syndrome. Always taper slowly. Educate patients never to stop abruptly.
- Tizanidine hepatotoxicity: Monitor LFTs. Discontinue if AST/ALT >3× ULN. Contraindicated with CYP1A2 inhibitors (fluvoxamine, ciprofloxacin — dramatically increases tizanidine levels).
- Generalized weakness: Oral agents reduce tone globally, including muscles where tone is functionally beneficial. Patients may report feeling weaker or less stable after starting oral antispastics. Dose-response is unpredictable.
5. Intrathecal Baclofen (ITB)
Intrathecal baclofen delivers baclofen directly to the spinal cord CSF via a surgically implanted programmable pump (typically SynchroMed II, placed subcutaneously in the abdominal wall) connected to an intrathecal catheter. This bypasses the blood-brain barrier, achieving CSF concentrations 10–100× higher than oral dosing at 1/100th the oral dose, dramatically reducing systemic side effects (sedation, cognitive impairment).
Indications
- Severe, generalized spasticity (MAS 3–4) affecting predominantly the lower extremities
- Refractory to optimized botulinum toxin and oral agents
- Spasticity causing significant pain, positioning difficulty, skin breakdown, or hygiene impairment
- Patient goals may be passive (ease of care, positioning, hygiene) rather than active function
- Trial response: Before pump implantation, a screening test is performed — intrathecal bolus (typically 50 μg baclofen via lumbar puncture) with MAS reassessment at 4 hours. A ≥1-grade MAS reduction supports proceeding with pump placement
Dosing and Management
Initial pump dose typically starts at twice the screening dose per 24 hours, delivered as continuous infusion. Dose titration occurs over weeks to months (usual maintenance: 100–900 μg/day, some patients require >1000 μg/day). Pump refills are required every 1–6 months depending on dose and reservoir size. The pump battery lasts approximately 7 years, requiring surgical replacement.
| Consideration | Details |
|---|---|
| Advantages over oral | Minimal systemic side effects, programmable dosing (can adjust rate by time of day — higher nighttime for spasms, lower daytime for function), titratable, reversible (can turn off or reduce), effective for severe spasticity unresponsive to other treatments |
| Surgical risks | Infection (2–5%), CSF leak, seroma, catheter malfunction (kink, migration, disconnection — most common long-term complication at ~15–25%), pump pocket complications |
| Baclofen withdrawal emergency | Catheter malfunction or missed refill can cause life-threatening withdrawal: rebound spasticity, hyperthermia, rhabdomyolysis, multi-organ failure, death. This is a medical emergency. Treat with high-dose oral baclofen, IV benzodiazepines, dantrolene, ICU admission. Prevention: never miss pump refills, educate patients and caregivers, ensure emergency department awareness. |
| Baclofen overdose | Programming error or catheter migration can cause overdose: flaccidity, respiratory depression, coma. Treat with pump deactivation, supportive care, consider CSF drainage. |
| Long-term maintenance | Requires reliable patient/caregiver, access to pump refill center, lifelong commitment. Pump replacement surgery every ~7 years. MRI compatibility varies by pump model (confirm before any MRI). |
6. Chemodenervation: Phenol & Alcohol Nerve Blocks
Before botulinum toxin became widely available, phenol (5–7%) and alcohol (50–100%) motor point or nerve blocks were the primary chemodenervation techniques. They remain useful in specific situations:
| Feature | Phenol / Alcohol Block | Botulinum Toxin |
|---|---|---|
| Mechanism | Chemical neurolysis — destroys nerve fibres (non-selective: motor and sensory) | Reversible chemodenervation — blocks ACh release at NMJ only |
| Onset | Immediate (within minutes) | 3–7 days |
| Duration | 3–12 months (nerve regeneration occurs) | 3–4 months |
| Cost | Very low ($10–50 per treatment) | High ($1,000–3,000+ per session depending on dose/formulation) |
| Adverse effects | Dysesthesia/neuropathic pain (if mixed sensory-motor nerve is targeted — common with obturator nerve), local tissue necrosis, fibrosis with repeated injections | Local weakness (intended), rare systemic effects, antibody formation |
| Best indications | Large muscles where botulinum toxin dose would be prohibitive (e.g., hip adductors — obturator nerve block); resource-limited settings; patients with botulinum toxin antibodies | Most focal spasticity patterns; muscles near sensory nerves; repeated injections needed; fine-dose titration important |
Common phenol nerve blocks in stroke: Obturator nerve block for hip adductor spasticity (scissoring gait), musculocutaneous nerve block for elbow flexion spasticity (biceps/brachialis), tibial nerve motor branches for equinovarus. Requires EMG or US guidance for nerve localization. Phenol is best reserved for pure motor nerves or motor points to avoid the complication of post-procedure dysesthesia.
7. Physical & Adjunctive Interventions
Non-pharmacologic modalities are essential components of spasticity management — they should be combined with chemodenervation, not used as standalone alternatives for moderate-to-severe spasticity.
| Intervention | Mechanism / Technique | Evidence & Role |
|---|---|---|
| Sustained stretching | Prolonged low-load stretch (30–60 minutes) via positioning, splints, or standing frames maintains muscle length and reduces passive stiffness | Cornerstone of contracture prevention. Must be performed daily. Best evidence when initiated early and combined with botulinum toxin during the peak effect window. |
| Serial casting | Progressive plaster/fiberglass casts applied at maximum comfortable stretch, changed every 5–7 days to gradually increase ROM | Best evidence for fixed contractures (small R2 − R1 difference). Most effective at ankle (equinus contracture) and elbow. Combine with botulinum toxin: inject first, cast at 1 week when spasticity is reduced. Risk: skin breakdown, DVT (limb immobilization). |
| Splinting / Orthoses | Resting hand splint (wrist/finger extension), AFO (ankle), dynamic elbow splint. Worn several hours daily or at night. | Maintains ROM gained from botulinum toxin and stretching. Prevents recurrence of contracture between injection cycles. Custom-molded preferred over off-the-shelf for comfort and compliance. |
| FES (Functional Electrical Stimulation) | Stimulation of antagonist muscles (e.g., wrist extensors) provides reciprocal inhibition of spastic agonists (wrist flexors) | Moderate evidence for temporary spasticity reduction and functional improvement. Combines well with task-specific practice. Also strengthens weak antagonists. |
| Extracorporeal shockwave therapy (ESWT) | Radial or focused shockwaves applied to spastic muscle belly | Emerging evidence from multiple RCTs showing MAS reduction for 4–12 weeks. Mechanism unclear (possibly reduced muscle fibrosis, Golgi tendon organ stimulation). Non-invasive, no systemic effects. May extend botulinum toxin effect when used in combination. |
| Whole-body vibration | Patient stands/sits on vibrating platform (20–50 Hz) | Some evidence for temporary spasticity reduction and improved balance. Mechanism involves Ia afferent activation and reciprocal inhibition. Easily accessible, safe. Modest effect size. |
8. Treatment Algorithm
A stepwise approach to spasticity management, integrated across the rehabilitation timeline:
| Phase | Timing | Interventions | Goals |
|---|---|---|---|
| Prevention | Day 1 onward | Proper positioning (anti-spastic patterns), early PROM, avoid noxious stimuli (UTI, pressure ulcers, constipation — all worsen spasticity), education | Delay onset, reduce severity, prevent contracture |
| Early spasticity (MAS 1–1+) |
Weeks 1–4 | Stretching program, splinting, positioning optimization, treat aggravating factors, consider tizanidine 2 mg at night if spasms disrupt sleep | Maintain ROM, manage symptoms, support rehab participation |
| Focal spasticity (MAS 2–3) |
Weeks 4+ | Botulinum toxin to specific muscles causing the functional problem + PT/OT stretching and functional therapy during the 2–6 week peak effect + splinting/casting | Reduce focal spasticity to enable function, hygiene, or pain relief. Repeat injections every 12–16 weeks. |
| Generalized / refractory | Months 3+ | Add low-dose oral agent (baclofen or tizanidine) to botulinum toxin regimen. Consider phenol for large muscles. Evaluate for ITB if lower limb predominant and refractory. | Multimodal control. Optimize for patient goals (active function vs passive care). |
| Severe / fixed | Chronic | ITB pump for generalized LE spasticity. Surgical tendon lengthening or release for fixed contractures (last resort). STFR (selective tibial fascicular rhizotomy) or other selective neurosurgical procedures in specialized centers. | Comfort, positioning, hygiene, skin integrity, pain management. Functional goals may shift to passive care. |
🔹 Clinical Relevance: Aggravating Factors — The "Spasticity Checklist"
- Spasticity can worsen acutely from noxious stimuli below the level of cortical awareness. Before adjusting antispastic medications, always check for and treat these common aggravating factors:
- Urinary: UTI, urinary retention, blocked catheter
- Bowel: Constipation, fecal impaction
- Skin: Pressure ulcers, ingrown toenails, tight clothing/shoes, poorly fitted orthotic
- Pain: Any untreated pain source (shoulder subluxation, heterotopic ossification, DVT)
- Positioning: Improper seating/wheelchair setup, uncomfortable bed surface
- Infection: Pneumonia, cellulitis, abscess
- Psychosocial: Anxiety, emotional distress (can transiently increase tone)
- Resolving the aggravating factor often reduces spasticity without medication changes.
9. Spasticity & Related Conditions Cross-Reference
Hemiplegic shoulder pain: Spastic shoulder internal rotators (subscapularis, pectoralis major) are a major contributor to shoulder pain through impingement and restricted ROM. Botulinum toxin to these muscles is first-line when spasticity is the dominant mechanism. See the Neuropsychiatric & Pain Syndromes article for comprehensive hemiplegic shoulder pain management.
Spasticity-related pain vs central post-stroke pain: Spasticity pain is nociceptive (cramping, aching, worsened by stretch, relieved by botulinum toxin). Central post-stroke pain is neuropathic (burning, allodynia, responds to amitriptyline/lamotrigine). These frequently coexist, requiring separate treatment strategies for each component.
Neuromodulation and spasticity: Both vagus nerve stimulation (VNS-REHAB) and spinal cord stimulation (SCS for Post-Stroke Hemiparesis) demonstrated spasticity reduction as secondary outcomes. If these modalities become widely available, they may address spasticity and motor weakness simultaneously — a significant advantage over botulinum toxin, which reduces spasticity but can weaken muscles further.
10. Trial & Evidence Comparison Table
| Intervention / Evidence Source | Level of Evidence | Key Finding | Clinical Implication |
|---|---|---|---|
| OnabotulinumtoxinA (UE spasticity) | Level A (AAN, multiple RCTs) | Consistent MAS reduction of 1–2 grades across multiple pivotal trials. Improved passive function and pain. Functional gains best when combined with therapy. | First-line for focal UE spasticity. Dose 200–400 U distributed across pattern-specific muscles. |
| AbobotulinumtoxinA (LE spasticity) | Level A (multiple RCTs) | Significant MAS reduction in ankle plantarflexors. Improved gait speed in some studies. Upper limb data also available. | First-line for focal LE spasticity. Dose 1000–1500 U for LE patterns. |
| Intrathecal baclofen | Level B (RCTs in mixed populations; stroke subgroup data limited) | Significant spasticity reduction (MAS), improved comfort and care in severe spasticity. Most data from SCI/MS populations. | Reserve for severe generalized LE spasticity refractory to botulinum toxin + oral agents. Trial dose before implantation. |
| Oral baclofen | Level C for stroke (extrapolated from SCI/MS) | Reduces tone globally but causes sedation, cognitive impairment. No stroke-specific RCTs showing functional benefit. | Adjunct only. Use lowest effective dose. Consider nighttime dosing for spasms. |
| Tizanidine | Level C for stroke | Small stroke-specific trials show MAS reduction comparable to baclofen with possibly less weakness. Hepatotoxicity risk. | Alternative to baclofen. Monitor LFTs. Useful as nighttime agent for nocturnal spasms. |
| Serial casting + botulinum toxin | Level B (RCTs) | Combined approach produces greater ROM gains than either alone. Most effective for equinus contracture at ankle. | Inject first, cast at 1 week. Change cast every 5–7 days for 3–4 cycles. |
| VNS-REHAB | Level B-R (pivotal RCT) | Spasticity reduction as secondary outcome in chronic stroke UE recovery trial. | Potential dual benefit for motor recovery + spasticity. FDA-approved for motor recovery, not spasticity specifically. |
| SCS Hemiparesis | Feasibility (N=7) | Spasticity decreased in all 7 participants as secondary outcome. | Investigational. May address motor weakness and spasticity simultaneously — conceptually superior to botulinum toxin. |
References
- Simpson DM, et al. Practice guideline update: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology. 2016;86:1818–1826.
- Wissel J, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009;41:13–25.
- Winstein CJ, et al. Guidelines for adult stroke rehabilitation and recovery: AHA/ASA guideline. Stroke. 2016;47:e98–e169.
- Brashear A, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347:395–400.
- Gracies JM, et al. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil. 2009;90:9–16.
- Ward AB, et al. Functional goal achievement in post-stroke spasticity patients: the BOTOX Economic Spasticity Trial (BEST). J Rehabil Med. 2014;46:504–513.
- Demetrios M, et al. Multidisciplinary rehabilitation following botulinum toxin and other focal intramuscular treatment for post-stroke spasticity. Cochrane Database Syst Rev. 2013;6:CD009689.
- McIntyre A, et al. Systematic review of the effectiveness of pharmacological interventions in the treatment of spasticity of the hemiparetic lower extremity more than six months post stroke. Top Stroke Rehabil. 2012;19:479–490.
- Baguley IJ, et al. International consensus statement on intrathecal baclofen use for acquired brain injury. Brain Inj. 2017;31:1583–1596.
- Picelli A, et al. Effects of extracorporeal shock wave therapy on spasticity in chronic stroke patients: a systematic review and meta-analysis. J Phys Ther Sci. 2019;31:657–662.
- Prabhakaran S, et al. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2026;57:e00–e00.
- Dawson J, et al. Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB). Lancet. 2021;397:1545–1553.
- Powell MP, et al. Epidural stimulation of the cervical spinal cord for post-stroke upper-limb paresis. Nature Med. 2025.